Kotecki N, et al. - In patients with advanced soft tissue sarcoma, researchers evaluated the influence of trabectedin interruption and ensuing rechallenge on progression via randomly assigning patients who were free from progressive disease (PD) either to continuous treatment with trabectedin (C arm) or therapy interruption (I arm), after the 6 initial cycles of trabectedin. An association was found between continuous treatment with trabectedin and significant improvement in progression-free survival vs the rechallenge arm, after a median follow-up from randomization of 35.3 months. The results from the T-DIS trial indicate that trabectedin holds its activity when patients are rechallenged on progression after a treatment break. The safety profile was similar in both arms.